Home › Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis clinical trials recruiting in the U.S.
17 studies for Focal Segmental Glomerulosclerosis are recruiting participants at sites across the United States.
Cities with the most studies
- Philadelphia, PA9 studies
- Durham, NC8 studies
- New York City, NY7 studies
- Miami, FL6 studies
- Los Angeles, CA6 studies
- Ann Arbor, MI6 studies
- Queens, NY6 studies
- Houston, TX5 studies
- Atlanta, GA5 studies
- Dallas, TX4 studies
- Cleveland, OH4 studies
- Kansas City, MO4 studies
- Chicago, IL4 studies
- Charleston, SC3 studies
- Orlando, FL3 studies
- Minneapolis, MN3 studies
- Seattle, WA3 studies
- Columbus, OH3 studies
- San Francisco, CA3 studies
- Baltimore, MD3 studies
- Kansas City, KS3 studies
By state
- California8 studies
- Colorado4 studies
- Delaware3 studies
- Florida7 studies
- Georgia6 studies
- Illinois4 studies
- Kansas3 studies
- Maryland4 studies
- Michigan10 studies
- Minnesota5 studies
- Missouri5 studies
- New York11 studies
- North Carolina9 studies
- Ohio8 studies
- Pennsylvania9 studies
- South Carolina6 studies
- Texas5 studies
- Washington3 studies
Recently updated studies
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
RecruitingPhase 2
Ages 18 to 115 · All sexes · Updated Sep 28, 2026 · NCT06664814A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 17, 2026 · NCT07220083Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Recruiting
Up to age 75 · All sexes · Updated Aug 28, 2026 · NCT04065438Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Recruiting
Up to age 21 · All sexes · Updated Aug 28, 2026 · NCT02235857A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT07268638Nephrotic Syndrome Study Network
RecruitingObservational study
Up to age 80 · All sexes · Updated Jun 10, 2026 · NCT01209000NEPTUNE Match Study
Recruiting
Ages 1 to 80 · All sexes · Updated Jun 10, 2026 · NCT04571658Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RecruitingObservational study
All ages · All sexes · Updated Apr 29, 2026 · NCT05650619A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Recruiting
Ages 3 to 17 · All sexes · Updated Apr 17, 2026 · NCT05583942taVNS for FRNS in Children
Recruiting
Ages 3 to 17 · All sexes · Updated Apr 15, 2026 · NCT05588063SLIT ABS: Study on Patients With Autoimmune Podocytopathy
Recruiting
Ages 0 to 99 · All sexes · Updated Apr 8, 2026 · NCT07516964AMPK-activation by Metformin in FSGS: AMP-FSGS
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Feb 3, 2026 · NCT06090227A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
RecruitingPhase 3
Ages 12 to 80 · All sexes · Updated Feb 3, 2026 · NCT05183646Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RecruitingObservational study
Ages 2 and older · All sexes · Updated Dec 22, 2025 · NCT05505500Proteinuria in Pre and Post Transplant
RecruitingObservational study
Up to age 25 · All sexes · Updated Nov 21, 2025 · NCT01094327From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.